Epitracker's Product Portfolio
Epitracker currently has four exciting projects in its product portfolio focusing on diagnosing and treating metabolic syndrome, slowing senescence (aging), repairing skin, and enabling early, blood-based detection of dementia. Early discovery research supported by the Office of Naval Research has helped to improve dolphin health and is also leading to potential life-saving therapeutic approaches for people in each of these areas.
ETI-101 for Metabolic Syndrome
ETI-101, Epiracker's lead lipid-based and patent pending oral therapeutic, is being developed to treat metabolic syndrome. Early studies suggest that ETI-101 provides broad cardiometabolic benefits.
ETI-100 is currently entering preclinical studies toward FDA's Investigational New Drug Approval.
Epitracker Patent Portfolio
Epitracker's lipid-based therapeutic platform is being developed as part of an exclusive license with the U.S. Navy to commercialize products under one awarded and nine pending U.S. and international patents (Space and Naval Warfare Systems Center Pacific Agreement Number PLA-SSCPacific-15-002).
Preliminary oral bioavailability studies have demonstrated that ETI-101's clinical compound levels rise in serum within 30 minutes and reached peak levels at 4 hours.
A preliminary efficacy study using daily oral ETI-101 for 12 weeks to treat metabolic syndrome in animal models demonstrated lower glucose, insulin, lipids, and inflammation compared to vehicle controls. There were no observational negative changes in behavior or health and no negative histologic changes in the liver in the treated group.
ETI-101 Mechanism of Action
Early in vitro studies support that ETI-101's broad cardiometabolic effects may be due in part to its role as a dual, partial peroxisome proliferator-activated receptor (PPAR) agonist. PPARs are well known orchestrators of metabolism, and compounds that serve as PPAR agonists can be effective in treating metabolic conditions.
There is currently no single drug to treat metabolic syndrome. Currently, people are prescribed different drugs for each of metabolic syndrome's components. This may include glitazones for insulin resistance, metformin for high glucose, fibrates for high triglycerides, and ACE inhibitors of high blood pressure. Current research with ETI-101's clinical compound suggests that it may help treat early, upstream causes of metabolic syndrome, potentially negating the need to treat its downstream components.